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Abstract 
Aim: The aim of this systematic review was to: (1) critically appraise, 
synthesise, and present the available evidence on the views and experiences of 
stakeholders on pharmacist prescribing and; (2) present the perceived 
facilitators and barriers for its global implementation. 
Methods: Medline, CINAHL, International Pharmaceutical Abstracts, 
PsychArticles, Google Scholar databases were searched. Study selection, quality 
assessment, and data extraction were conducted independently by two 
reviewers. A narrative approach to data synthesis was undertaken due to 
heterogeneity, the nature of study types and outcome measures. 
Results: Sixty-five studies were identified, mostly from the United Kingdom 
(n=34), followed by Australia (n=13), Canada (n=6), United States (n=5). 
Twenty-seven studies reported pharmacists’ perspectives, with fewer studies 
focusing on patients’ (n=12), doctors’ (n=6), the general public’s (n=4), nurses’ 
(n=1), policymakers’ (n=1), multiple stakeholders’ (n=14) perspectives. Most 
reported positive experiences and views, regardless of stage of implementation. 
The main benefits described were: ease of patient access to healthcare services, 
improved patient outcomes, better utilisation of pharmacists’ skills and 
knowledge, improved pharmacist job satisfaction, and reduced physician 
workload. Any lack of support for pharmacist prescribing was largely around: 
accountability for prescribing, limited pharmacist diagnosis skills, lack of access 
to patient clinical records, and issues around organisational and financial 
support. 
Conclusion: There is an accumulation of global evidence of the positive views 
and experiences of diverse stakeholder groups and their perceptions of 
facilitators and barriers to pharmacist prescribing. There are, however, 
organisational issues to be tackled which may otherwise impede the 
implementation and sustainability of pharmacist prescribing. 
Keywords: prescribing, clinical pharmacy, systematic review  
What is already known about the subject 
 Many countries around the world are implementing legislation, policies and 
practices relating to pharmacist prescribing 
 Systematic reviews have documented some evidence of effectiveness and 
safety of non-medical prescribing 
What this review adds 
 Synthesis of data from a large number of studies in many countries from the 
perspectives of diverse groups of stakeholders provides further evidence of 
the positive views and experiences around pharmacist prescribing 
 There are organisational issues of role recognition, access to patient clinical 
information and financial support which could impede the implementation and 
sustainability of pharmacist prescribing  
Introduction 
While prescribing has traditionally been restricted to medical practitioners 
(doctors and dentists), the rapid advancements in healthcare policies and 
practices have led to the introduction of models of non-medical prescribing in 
several countries, with others exploring its potential [1, 2]. Non-medical 
prescribing is most developed in the United Kingdom (UK), with legislative 
changes enabling the implementation of supplementary prescribing (SP) in 2003 
and independent prescribing (IP) in 2006, as described in Table 1. 
Implementation is most advanced in Scotland, and particularly for pharmacists, 
where approximately 40% of pharmacists in 2017 were either prescribers 
registered with the General Pharmaceutical Council or undertaking an approved 
training programme [7]. Developments in Scotland are supported by the policy 
driven approach of the Scottish Government, articulated in 2013 with the 
publication of “Prescription for Excellence: a vision and action plan for the right 
pharmaceutical care through integrated partnerships and innovation” [8]. This 
outlined the goal that “all patients, regardless of their age and setting of care, 
receive high quality pharmaceutical care from clinical pharmacist independent 
prescribers” [8]. The aspiration is that all patient-facing pharmacists will be 
clinical pharmacist independent prescribers by 2023. This commitment to 
developing the clinical prescribing role of pharmacists in all practice settings was 
reaffirmed in 2017 with publication by the government of “Achieving Excellence 
in Pharmaceutical Care” [7]. Details of other models of pharmacist prescribing 
which have been implemented in the United States (US), Canada, and New 
Zealand are given in Table 2, highlighting the diverse scope of prescribing rights. 
There is increasing evidence of the effectiveness and safety of pharmacist 
prescribing. A recently published Cochrane review of 46 studies (37,337 
participants) of prescribing by pharmacists (20 studies) and nurses (26 studies) 
compared to medical prescribing for a range of acute and chronic conditions 
included meta-analyses of surrogate clinical markers [13]. The review concluded 
that non-medical prescribers, practising with varying but high levels of 
prescribing autonomy, in a range of settings, were as effective as usual care 
medical prescribers. Non-medical prescribers recorded comparable outcomes for 
systolic blood pressure, glycated haemoglobin, low-density lipoprotein 
cholesterol, medication adherence, and health-related quality of life . There is 
also emerging evidence of safety with pharmacist prescribers in Scotland 
performing well in pilot studies of the UK Prescribing Safety Assessment [14]. 
This evidence of effectiveness has the potential to support pharmacist 
prescribing developments across the world. In addition, feedback from key 
stakeholder groups in terms of their views and experiences about pharmacists 
prescribing is vital in order to determine the possible factors influencing its 
implementation and thus inform the development and realisation of such 
initiatives in other countries. Such ‘stakeholders’, are defined in the context of 
health and associated research by the Agency for Healthcare Research and 
Quality [15] as, “persons or groups that have a vested interest in a clinical 
decision and the evidence that supports that decision”. Examples of health 
stakeholders include patients, clinicians, advocacy groups, and policymakers, all 
of whom have roles in developing, implementing, delivering, experiencing or 
evaluating non-medical prescribing interventions.  
The aim of this systematic review was to critically appraise, synthesise, and 
present the available evidence on the views and experiences of stakeholders on 
pharmacist prescribing, including potential facilitators and barriers, regardless of 
implementation status. 
Methods 
A systematic review protocol was developed, in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) 
standards, and registered on International Prospective Register of Systematic 
Reviews (PROSPERO) at the Centre for Reviews and Dissemination in the UK 
(CRD42016048072) [16]. 
Inclusion criteria 
Studies reporting views and/or experiences of any stakeholder group (e.g. 
patients, general public, physicians, nurses, pharmacists) pertaining to 
pharmacist prescribing, irrespective of the stage of implementation (pre or 
post), model of prescribing (e.g. supplementary, independent or collaborative), 
with no date or language limit up to November 2017, were included in this 
systematic review. All peer-reviewed, primary research studies were included, 
while literature reviews, narrative reports, and editorials were excluded. The 
inclusion process was performed by TJ and reviewed by DS. 
Search strategy 
The search string applied to Medline is given in Box 1; and adapted for 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), International 
Pharmaceutical Abstracts (IPA), PsychArticles, and Google Scholar. The 
reference lists of all identified articles in the full text screening were searched 
manually for potentially eligible studies meeting the review criteria. 
Assessment of methodological quality 
Quality assessment was undertaken by two independent reviewers using the 
Mixed Methods Appraisal Tool (MMAT) [17], which permits the appraisal of 
qualitative, quantitative, and mixed methods studies. Consensus was reached 
through discussion or by a consultation with a third reviewer. 
Data extraction 
Data extraction was performed by two independent reviewers, with a third 
included if any disagreement occurs. Data items extracted were: stated 
aim/objective, phase of implementation (pre vs post), country of focus, model of 
prescribing, stakeholder group, study design, and key findings. 
Data synthesis 
Due to heterogeneity of phase of implementation, models of prescribing, study 
designs, and variability of data collection tools, a meta-analysis approach of 
quantitative findings was not possible. Hence, a narrative approach to data 
synthesis was applied. Pooling of qualitative research findings involved the 
aggregation or synthesis of findings to generate a set of statements that 
represented that aggregation, through assembling and categorising findings 
based on similarity in meaning.  
Results 
The electronic search yielded 331 studies. Removal of duplicates resulted in 273 
articles, 226 of which were excluded based on title, abstract, or full-text review. 
An additional 18 studies were identified from other sources (e.g. reference lists) 
resulting in 65 eligible studies for quality assessment and data extraction. The 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram is provided in Figure 1. 
Quality of included studies 
Most studies employed quantitative designs, largely questionnaire-based survey 
methodology (n=41) [18-58], with fewer qualitative designs (n=21) [59-79]. 
The remaining three studies were sequential explanatory mixed methods studies 
all with survey followed by either focus group discussions [80, 81] or interviews 
[82]. Quality assessments given in Figure 2 highlight the largely robust and 
rigorous nature of the studies reviewed.  
The key limitations of the survey studies were the lack of details around 
sampling strategies and the stages of questionnaire development, review, and 
piloting. Only 14 studies had achieved the MMAT target response rate of 60% 
[19, 22-26, 29, 32, 36, 39, 40, 52, 54, 57]. Qualitative studies lacked details of 
approaches to ensuring data trustworthiness and the mixed methods studies 
provided limited information on integrating quantitative and qualitative data. 
However, all the 65 studies had sufficient robustness and rigour to be included in 
the stages of data extraction and synthesis.  
Characteristics and key findings of included studies 
The extracted data are summarised in Tables 3, 4, and 5 for the quantitative, 
qualitative, and mixed methods studies respectively. 
Of the 65 studies, 29 (45%) were conducted prior to the implementation of 
pharmacist prescribing in the country of study [18, 38-57, 74-79, 81, 82], while 
the remaining 35 (54%) were conducted post-implementation [19-37, 58, 59, 
61-73, 80]. Only one study explored views and experiences pre- and post-
registration [60]. 
Most of the included studies were conducted in the UK (n=34, 52%) [21-31, 33-
35, 37, 40-44, 59-69, 71, 73, 80], followed by Australia (n=13, 20%) [18, 45-
48, 51, 54-55, 74, 77, 79, 81, 82], Canada (n=6, 9%) [32, 36, 49, 58, 70, 76], 
US (n=5, 8%) [19-20, 38-39, 72], Nigeria (n=4, 6%) [50, 52, 56, 78], and one 
each for Ireland [53], India [57], and New Zealand [75]. 
The main stakeholder group studied was pharmacists (n=27, 42%), including 
those registered as prescribers [22, 26, 29, 63, 67, 80], non-prescribers [23, 
24, 30, 32, 44-48, 51, 55, 56, 73-74] or mixed prescribers and non-prescribers 
[19, 20, 37, 58, 60, 66, 70]. Fewer studies investigated the perceptions of 
patients (n=12, 19%) [18, 25, 27, 31, 34, 36, 38, 52, 54, 64, 68, 71], doctors 
(n=6, 9%) [21, 40, 42, 61, 75, 82], the general public (n=4, 6%) [28, 33, 49, 
57], nurses (n=1, 2%) [43], or policymakers (n=1, 2%) [76]. Fourteen studies 
reported multiple stakeholder perspectives [35, 39, 41, 50, 53, 59, 62, 65, 69, 
72, 77-79, 81]. 
While most studies (n=41, 63%) provided a standardised or legislative definition 
of pharmacist prescribing, 24 (37%) did not [19, 21, 25, 30, 31, 36, 37, 38, 40-
43, 46, 49-50, 52-54, 57, 73, 77-80]. 
For quantitative studies, the sample size ranged from 105 to 4158, with 
response rates of 6.4% to 87%. On the other hand, qualitative studies included 
between 8 and 82 participants. For mixed methods studies, the sample size in 
the quantitative element ranged from 15 to 179, with response rates of 15% to 
100%, while the number of participants in the qualitative element ranged from 8 
to 10. 
Stakeholders’ views and experiences of pharmacist prescribing 
The majority of both pre- and post-implementation studies included reported 
support for prescribing pharmacists. 
Pre-implementation studies 
a. General public: 
Two studies investigated the public’s perceptions of granting pharmacists the 
authority to prescribe in Canada and India. Respondents were generally 
supportive of prescribing by pharmacists who received training in specific 
situations, which included: the physician having made the diagnosis, prescribing 
from a limited range, in emergency situations, prescribing alternative medicines 
for the same medical condition, renewing prescriptions, or modifying the 
strength or frequency of medicines prescribed by a physician [49, 57]. 
b. Patients: 
Studies of patients and patient group representatives reported support for 
pharmacist prescribing [18, 38, 52, 54, 78, 79], which was perceived as likely to 
improve access to healthcare generally and consultation with a trained health 
professional making better use of pharmacists’ skills [18, 52, 54, 79]. 
Respondents in several studies noted the need for the pharmacist prescribers to 
have undertaken additional training, after a physician’s diagnosis, and that 
prescribing should be from a restricted list of medicines [18, 52, 79]. 
c. Pharmacists: 
Pharmacists themselves were generally supportive of a prescribing role, which 
they perceived as a logical development given their expertise in medicines, their 
existing over-the-counter prescribing related activities, and their increasingly 
evolving clinical roles as part of the multidisciplinary team in secondary care. 
Moreover, they anticipated that outcomes would include quicker and easier 
patient access to medicines, promoting better utilisation of their skills with 
resultant enhanced status, as well as increased job satisfaction [41, 46-48, 50, 
51, 53, 74, 78, 79, 81]. There was agreement that they required additional 
training prior to assuming a prescribing role [41, 45, 46, 55, 56, 79]. 
There were diverse views on the models and scope of prescribing which ranged 
from prescribing within an agreed clinical management plan (CMP), repeat 
prescribing for stabilised chronic conditions, and modifying treatment based on 
the results of laboratory tests ordered by themselves [56, 74, 81]. Many 
respondents also viewed IP as appropriate for pharmacists, noting that it will be 
safe, effective, and improve patient access to medicines. They generally held the 
view that physicians would be in favour of pharmacist prescribing [51, 55]. 
d. Doctors: 
Studies conducted pre-implementation of pharmacist prescribing reported a 
range of views from doctors (n=9). In one study conducted in the UK, the 
majority of respondents were supportive, provided that additional postgraduate 
education/training was undertaken [41]. In other studies, physicians were more 
cautious in their support, but acknowledged that a model of pharmacist 
prescribing for limited conditions, such as minor ailments, was a logical 
development [40, 50, 53, 75, 78]. 
Other studies reported physicians’ concern over: pharmacists’ lack of clinical 
assessment and diagnosis skills, lack of access to individual patient medical 
records, legal considerations such as division of clinical responsibility of care, a 
potential negative effect on the physician-patient relationship, and issues around 
communication between the pharmacist prescriber and other members of the 
multidisciplinary team [42, 53, 82].  
e. Nurses: 
Two UK studies reported the perspectives of nurses with respondents 
considering pharmacist prescribing for existing or new therapy very useful due to 
their knowledge in pharmacology and a belief that it will be clearer and safer 
[41, 43]. 
f. Policymakers: 
Government and pharmacy policymakers from the US, Canada, and Nigeria 
anticipated benefit to pharmacist prescribing in terms of improved continuity of 
care, better patient outcomes, reduced prescribing costs, and reduced physician 
workload [39, 76, 78]. Concerns were, however, expressed by medical 
policymakers in relation to the need for additional training and access to 
individual patient medical records, without which there could be fragmented care 
[76]. 
Post-implementation studies 
a. General public: 
Two studies reported the perspectives of samples of the public, both exposed to 
pharmacist prescribing and not exposed to it, in the UK. Findings highlighted 
general support, particularly for the management of minor ailments and issuing 
repeat prescriptions. There were some concerns around pharmacists’ training in 
diagnosis, lack of access to patients’ medical records, and potential lack of 
privacy and confidentiality within a community pharmacy setting [28, 33]. 
 
b. Patients: 
Nine studies assessed the experience of patients who were exposed to 
pharmacist prescribing, while Hobson et al. included exposed and unexposed 
patients in the UK [64] and Feehan et al. had US patients who had never been 
exposed to pharmacist prescribing [72].  
The majority of those patients who had consulted with a pharmacist prescriber 
were highly satisfied with the consultation overall, particularly the pharmacist’s 
competence and capability, considering their prescribing to be as effective and 
safe as their physician. They also gave positive feedback relating to the 
pharmacist’s personality, knowledge and communication skills as well as the 
consistency, accessibility, length and outcome of the care received [25, 27, 31, 
34-36, 62, 64, 68, 71]. 
In a recent study of prescribing by community pharmacists in the US, patients 
who had yet to experience pharmacist prescribing were of the view that 
pharmacists should only dispense and provide medicines information other than 
a possible role in prescribing for minor conditions [72]. 
c. Pharmacists: 
Twenty-four studies researched the perspectives of pharmacists post-
implementation of prescribing rights mainly in the UK (n=18), US (3), and 
Canada (3). The pharmacists sample in these studies included either prescribers 
[22, 26, 29, 35, 59, 62, 63, 65, 67, 69, 80], non-prescribers [23, 24, 30, 32, 
72, 73], or both [19, 20, 37, 58, 60, 66, 70]. Pharmacists positively perceived 
this expanded professional role and reported that drivers to undertake 
pharmacist prescribing include developing a clinical role, better patient 
management, personal development, enhancing job and patient satisfaction, 
improving self-confidence as well as reducing cost of therapy [19, 20, 22-24, 26, 
29, 30, 32, 35, 37, 58-60, 62, 63, 65-67, 69, 70, 73, 80]. 
Studies also concluded that implementing pharmacist prescribing was easier in 
secondary care compared to primary or community care due to logistics related 
to access to medical records and networking environment [29, 59, 65, 70, 80]. 
Negative attitudes towards prescribing pharmacists were mainly related to 
increased liability, lack of time to engage in prescribing, and lack of experience 
in diagnosis in addition to medical resistance and difficulties in developing a CMP 
for every patient [19, 29, 30, 59, 60, 65, 66, 70]. 
Due to liability and diagnosis-related issues, pharmacists preferred SP or 
prescribing for minor and chronic conditions [63, 66, 72]. However, other 
studies reported that SP was not believed to significantly save physicians’ time 
or improve patient care due to the limited list of drugs they can prescribe under 
the CMP. Thus, IP will have a better impact [24, 29, 35, 62, 63, 65, 67]. 
d. Doctors: 
Seven studies explored doctors’ perceptions of this new role for pharmacists, all 
of which were conducted in the UK. Of those, six studies reported the 
perspectives of doctors who had worked alongside pharmacist prescribers. The 
majority supported pharmacist prescribing across the studies with some benefits 
highlighted including more holistic and continuous patient care, better utilisation 
of pharmacists’ skills, effects of enhancing physicians’ medicines knowledge, and 
drug cost saving [59, 61, 62, 65, 69]. While physicians reported reduced direct-
patient workload, the need to develop individual patient CMPs for SP was 
burdensome hence the impending implementation of IP was welcomed [35]. 
The only study that investigated doctors who were not exposed to prescribing 
pharmacists reported that, with time, doctors are more likely to accept this new 
role [21]. 
e. Policymakers: 
Only one study from the US explored the perceptions of policymakers involved in 
medical services coverage or formulary policies after the realisation of 
pharmacist prescribing. The main findings were that these decision-makers 
responded positively to pharmacist prescribing due to pharmacists’ knowledge 
about drugs and their mechanisms of action [72]. 
Facilitators of and barriers to pharmacist prescribing implementation 
Many studies (n=27, 42%) reported facilitators and barriers to the 
implementation of pharmacist prescribers as perceived by the different 
stakeholder groups [22-24, 26, 29, 37, 45, 46, 48, 50, 51, 56, 58-60, 62, 64, 
65, 67, 69, 70, 72, 73, 77, 78, 80, 81] which are summarised in Table 6. 
The major facilitators to this role include pharmacist personal qualities 
(enthusiasm, communication skills, experience and training), practice setting 
(working in an interprofessional team), organisational, managerial and medical 
colleagues’ support as well as infrastructure and resources (number of 
pharmacist available, space and access to medical records) [22, 23, 58, 59, 67, 
69, 70]. 
The main barriers reported are pharmacists’ poor clinical skills if not prescribing 
collaboratively and issues relating to resources (access to medical records, 
shortage in pharmacy workforce, funding, time), support (doctors opposition), 
logistics (accountability, conflict of interest, referral process) and poor 
recognition of pharmacy profession [22, 24, 26, 29, 45, 46, 48, 50, 51, 56, 58-
60, 62, 64, 65, 69, 72, 73, 77, 78, 80, 81]. 
Discussion 
This systematic review summarises the evidence around the views and 
experiences surrounding pharmacist prescribing from the perspectives of a 
diverse range of stakeholders in a range of countries and settings. 
The majority of studies pre- and post-implementation reported positive views 
and experiences with main benefits described as: increased access to healthcare 
services, perceptions of enhanced patients’ outcomes, better utilisation of 
pharmacists’ skills and knowledge, improved job satisfaction, and reduced 
physicians’ workload. However, concerns were noted around issues of: liability, 
limited pharmacists’ diagnosis skills, access to medical records, and lack of 
organisational and financial support. While review findings are derived from 
many studies of generally high methodological quality, there is a lack of mixed-
methods approaches. These are being used increasingly within healthcare and 
allow both quantification of findings and in-depth exploration of key issues [83]. 
Healthcare policies in countries such as the UK are supporting the expansion of 
pharmacist prescribing and indeed there is a move to increase the number of 
pharmacists practicing within primary care practices [84]. The positive findings 
of this systematic review, together with previous reviews of effectiveness and 
safety [13, 85-88], provide evidence to support such developments. 
Furthermore, such review findings are important in those countries and settings 
starting to explore and develop models of pharmacist prescribing 
[2].Interpretation and extrapolation of findings from studies conducted pre-
implementation are limited in that participants may not be fully aware of the 
aim, nature, and scope of the intervention and may be influenced by experiences 
of similar or diverse interventions. This is apparent in terms of concerns around 
independent prescribing models in the UK and pharmacists’ limited training in 
diagnosis. While this does allow assessment and prescribing of undiagnosed 
conditions, this must be within the prescribers’ competence and indeed most 
pharmacist independent prescribers practise with patients in whom diagnosis has 
already been established by the doctor [6]. Concerns such as liability and skills 
which were voiced pre-implementation were less common post-implementation 
as such studies allow participants to reflect on their real-life experiences. For 
example, doctors who had worked alongside pharmacist prescribers and patients 
managed by the pharmacists were very supportive of their professionalism and 
skills.  
While lack of access to medical records is an issue, most notably within 
community pharmacy settings, this is being addressed within the UK with 
pharmacists having access to specific limited sections of the electronic medical 
record [89]. Many of the barriers and indeed facilitators can be explained by 
theories of implementation. It is therefore notable that only three of the 65 
studies incorporated any mention of theory within the study design, conduct, 
and reporting [18, 58, 70]. There is a need for implementation studies to focus 
on theory to allow more systematic and comprehensive investigation of 
facilitators and barriers. Similarly, those planning implementation should include 
key theoretical elements at the outset in order to heighten the facilitators and 
lessen the barriers such as inadequate funding, access to resources, etc. The 
Consolidated Framework for Implementation Research (CFIR) is an integrative 
framework derived from many different theories. It is described in five domains 
of: intervention characteristics, outer setting, inner setting, characteristics of the 
individuals involved, and the process of implementation [90]. All barriers 
identified post-implementation of pharmacist prescribing (e.g. funding, access 
issues, etc.) would be eliminated in advance by employing CFIR since it can 
serve as a guide for implementing an innovation. However, it is likely that these 
barriers reflected the stage of implementation and are likely to have been 
resolved over time.  
Previous reviews have been limited in nature and rigour (thematic and scoping 
reviews), focused on pre-implementation, lacked quality assessment of included 
studies, and focused on limited ranges of stakeholders in specific countries (UK 
and Canada) [88, 91, 92]. This systematic review was conducted according to 
best practices and is reported in accordance with the PRISMA Statement 
standards [93]. Furthermore, it was not limited to a specific country, setting, 
stakeholder group, or implementation stage. However, the generalisability or 
transferability of findings to other countries or cultures may be limited given that 
almost all studies were conducted post-implementation in the western world and 
mainly focused on pharmacists’ perspectives. Moreover, several of these studies 
were conducted several years ago hence may no longer accurately reflect the 
current situation in those countries. While many implementation studies have 
been reported, it is still necessary to conduct such investigations in any country 
or setting planning to establish pharmacist prescribing to learn from the 
evidence-base. Future developments and studies should pay attention to 
theories of implementation and adopt mixed methods approaches with an 
inclusive range of stakeholders.  
Conclusion 
A large number of studies have reported stakeholders’ views and experiences of 
pharmacist prescribing, pre- and post-implementation. While studies were from 
a limited number of countries, the overwhelming finding was positive, 
particularly in relation to increased access to healthcare services, perceptions of 
enhanced patients’ outcomes, better utilisation of pharmacists’ skills and 
knowledge, improved job satisfaction, and reduced physicians’ workload. 
Concerns were largely identified pre-implementation and were around 
organisational issues and perceived lack of pharmacists’ diagnosis skills.  
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 Table 1: Characteristics of supplementary and independent prescribing in the UK [3, 4]  
 Supplementary Prescribing Independent Prescribing 
Year of Introduction in the UK 2003 2006 
Definition “A voluntary partnership between 
an independent prescriber (doctor 
or dentist) and a supplementary 
prescriber to implement an agreed 
patient-specific clinical 
management plan (CMP) with the 
patient’s agreement” [5] 
“The prescribing by a practitioner 
(e.g. doctor, dentist, nurse, 
pharmacist) responsible and 
accountable for the assessment of 
patients with undiagnosed or 
diagnosed conditions and for 
decisions about the clinical 
management required, including 
prescribing” [6] 
Eligible health professionals Dieticians, nurses, optometrists, 
pharmacists, physiotherapists, 
podiatrists, radiographers 
Nurses, optometrists, pharmacists, 
physiotherapists, podiatrists, 
therapeutic radiographers 
Clinical conditions managed Any, within their clinical 
competence 
Any, within their clinical 
competence 
Diagnosis responsibilities A doctor (or dentist) must diagnose 
the condition before prescribing 
can commence 
The independent prescriber can 
assess and manage patients with 
diagnosed or undiagnosed 
conditions 
Need for a Clinical Management 
Plan (CMP) 
A written or electronic patient-
specific CMP must be in place 
before prescribing can commence 
No need for a CMP 
Need for formal agreement The CMP must be agreed with the 
doctor (or dentist) and patient 
before prescribing can commence 
No need for any formal agreement 
Drugs prescribed Any, within their clinical 
competence 
Any licensed medicines within their 
clinical competence. Nurse- and 
pharmacist-independent 
prescribers in particular can 
prescribe unlicensed medicines and 
controlled drugs 
 
 
 
 
 Table 2: Summary of pharmacist prescribing models globally 
Country Prescribing Model Description 
United States of 
America (USA) 
Collaborative Drug Therapy Management 
(CDTM) 
Defined by the American College of Clinical Pharmacy (ACCP) as “a collaborative practice agreement 
between one or more physicians and pharmacists wherein qualified pharmacists working within the 
context of a defined protocol are permitted to assume professional responsibility for performing patient 
assessments; ordering drug therapy-related laboratory tests; administering drugs; and selecting, 
initiating, monitoring, continuing, and adjusting drug regimens” [9, 10]. 
According to the Centers for Disease Control, in 2012, majority of states allow CDTM for health 
conditions as specified in a written provider protocol in any setting (Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, 
Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, 
New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South 
Dakota, Utah, Vermont, Virginia, Washington, Wyoming), some limit it to certain health settings (New 
Hampshire, New York, Nevada, North Dakota, Texas, West Virginia) while others authorise extremely 
limited collaborative practice for pharmacists under protocol such as immunisations and emergency 
contraception regardless of setting (Delaware, Illinois, Kensas, Maine, Wisconsin) [10]. 
Canada The types and scope of pharmacist 
prescribing practice is variable according 
to province 
Legislations in Canada now allow pharmacists to prescribe within their area of competence and with 
sufficient clinical knowledge of the patient. 
The prescribing practice differ from one province to another. Pharmacists with additional training are 
able to prescribe any schedule 1 drug (except drugs under the Controlled Drugs and Substances Act) or 
alter another prescriber’s original prescription independently only in Alberta and under a collaborative 
agreement in Alberta, Saskatchewan, Manitoba, New Brunswick, and Nova Scotia. Moreover, they can 
change a drug’s dosage, formulation or regimen across the country, except in Northwest Territories, 
Yukon, and Nunavut. Furthermore, in Alberta, Manitoba, Quebec, and Nova Scotia, pharmacists are 
allowed to order and interpret laboratory tests [11]. 
New Zealand Pharmacist Prescriber (Collaborative 
Prescribing) 
According to Pharmacy Council of New Zealand [12], “pharmacist prescribers work in a collaborative 
health team environment with other healthcare professionals and are not the primary diagnostician. 
They can write a prescription for a patient in their care to initiate or modify therapy (including 
discontinuation or maintenance of therapy originally initiated by another prescriber). They can also 
provide a wide range of assessment and treatment interventions which includes, but is not limited to:  
 ordering and interpreting investigation (including laboratory and related tests) 
 assessing and monitoring a patient’s response to therapy 
 providing education and advice to a patient on their medicine therapy” 
 
 
 Box 1: Search string applied to Medline (title, abstract, keywords, subject heading) 
((view* OR perspective* OR perception* OR opinion* OR attitude* OR belief* OR thought* OR feel* OR 
impress* OR stance* OR viewpoint* OR standpoint* OR position* OR support* OR concern* OR confiden* 
OR expect*) 
OR 
(experience* OR satisf* OR reflect* OR react* OR content* OR understand* OR encounter* OR evaluat* OR 
feedback)) 
AND 
"pharmacist* prescrib*" 
  
 Table 3: Characteristics and key findings of included quantitative studies (n=41) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition and 
model of PP 
discussed 
Country of 
focus 
Stakeholder 
population studied 
(sample size) 
Study design 
and methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Pennock et al. 
(1988) [38] 
Explore to what extent will pharmacist 
prescribing be accepted by consumers  
No standardised 
definition provided 
USA  Consumers (n=400, 
response rate (RR) 
53%) 
Questionnaire Consumers’ relationships with 
pharmacists is important in 
determining acceptance of 
prescribing role. 
Segal and 
Grines (1988) 
[39] 
Identify attitudes of organised pharmacy, 
organised medicine and pharmaceutical 
industry about prescribing authority for 
pharmacists 
Models of PP in 
each US state 
presented 
USA Different pharmacy and 
medical associations and 
boards, Pharmaceutical 
Manufacturers 
Association (PMA), 
manufacturers and non-
PMA-member generic 
manufacturers (n=307, 
RR 63%) 
Questionnaire Hospital pharmacy 
associations/boards to a lesser 
extent in support; non-PMA-member 
generic manufacturers/US state 
pharmacy associations relatively 
neutral. Medical associations/PMA-
member companies in opposition.  
Spencer and 
Edwards (1992) 
[40] 
Ascertain GPs’ attitudes to an extended role 
for community pharmacists 
No standardised 
definition provided 
UK  Doctors (n=1087, RR 
68.4%) 
Questionnaire Pharmacists are too influenced by 
commercial pressures, should stick 
to dispensing and not supervise 
repeat prescriptions. However, GPs 
supported pharmacists prescribing 
nicotine chewing gum.  
Child, Hirsch 
and Berry 
(1998) [41] 
Identify the attitudes of hospital-based 
healthcare professionals involved in drug 
therapy towards prescription writing and 
initiation of drug treatment (“prescribing”) by 
the pharmacist, explore the perceived 
barriers to PP, and to examine the potential 
future role of the pharmacist in drug therapy 
management 
No standardised 
definition provided 
UK  Doctors (n=195, RR 
48.7%), nurses (n=200, 
RR 57.5%), pharmacists 
(n=87, 77%) 
Questionnaire Postgraduate education/training and 
attachment to clinical area are 
important requirements for PP. 
Barriers are pharmacists’ willingness 
to accept this role, 
education/training and 
accountability. 
Child and 
Cantrill (1999) 
[42] 
Examine the reasons behind hospital doctors’ 
perceived barriers to PP in the UK 
No standardised 
definition provided 
UK Hospital doctors 
(n=193, RR 49%) 
Questionnaire Awareness of clinical and patient 
details, communication, doctor 
writing initial prescription, clinical 
responsibility and review of 
treatment were reported. 
 Child (2001) 
[43] 
Examine hospital nurses' perceptions of PP in 
the UK 
No standardised 
definition provided 
UK  Nurses at five NHS 
teaching hospitals 
(n=200, RR 57.5%) 
Questionnaire Pharmacists’ knowledge, review of 
treatment, pharmacists' workload, 
communication and accountability 
issues were discussed. 
George et al. 
(2006b) [44] 
Investigate community pharmacists’ 
awareness, views and attitudes relating to IP 
by community pharmacists and their 
perceptions of competence and training 
needs for the management of some common 
conditions 
Provided definition 
of UK models 
UK  Community pharmacists 
(n=500, RR 43.4%) 
Questionnaire Confidence in abilities to IP, training, 
consultation skills and 
communication were highlighted. 
Facilitators include practising more 
hours/week as a pharmacist, 
training, and involvement in Scottish 
Executive pharmaceutical care model 
schemes. 
Kay, Bajorek 
and Brien 
(2006) [45] 
Identify Australian pharmacists’ awareness of 
their international colleagues’ prescribing 
practices and explore their views about the 
feasibility and utility of PP privileges within 
the scope of their current practice 
Provided definition 
of dependent 
prescribing 
Australia Pharmacists (n=4158, 
RR 6.4%) 
Questionnaire 74% and 52% supported dependent 
and independent prescribing 
respectively. 86% believed they 
could justify their prescribing while 
73% believed they would benefit 
from prescribing authority. 
Nguyen and 
Bajorek (2008) 
[46] 
Explore the clinical utility and capacity of 
pharmacists to undertake prescribing 
functions in anticoagulation management in 
the hospital setting (Pilot study) 
No standardised 
definition provided 
Australia  Pharmacists (n=16), 
graduates (n=2) and 
final year pharmacy 
students (n=6) 
Questionnaire Inpatient PP can be useful but 
outpatient and dependent models 
were more appropriate. 58% of 
prescribing was clinically 
inappropriate. Barriers include 
training, experience and doctors’ 
opposition. 
Weeks and 
Marriott (2008) 
[47] 
Explore the views of Society of Hospital 
Pharmacy Australia pharmacist members on 
collaborative prescribing and the extent of de 
facto prescribing at their institution 
Provided definition 
for collaborative 
and de facto 
prescribing 
Australia Pharmacists (n=1367, 
RR 40%) 
Questionnaire 95% thought collaborative 
prescribing could circumvent hospital 
delays with timely service delivery. 
If a framework existed, 75% would 
consider PP. 
Hoti et al. 
(2010) [48] 
Evaluate the views of Australian pharmacists 
on expanded PP roles and identify important 
drivers and barriers to its implementation 
Current practice of 
Australian 
pharmacists 
presented 
Australia  Pharmacists (n=2592, 
RR 40.4%) 
Questionnaire 83.9% supported PP and 97.1% 
needed training. Inadequate training 
in patient assessment, diagnosis and 
monitoring were barriers to PP. 
Hoti, Hughes 
and Sunderland 
(2011) [18] 
Examine the views of regular pharmacy 
clients on PP and employ agency theory in 
considering the relationship between the 
stakeholders involved 
Current practice of 
Australian 
pharmacists 
presented 
Australia  Patients (n=1153, RR 
34.7%) 
Interview 
(Quantitative 
approach) 
71% trusted PP, while 66% 
supported doctor diagnosing first. 
Pharmacist diagnosing and 
prescribing was limited to pain 
management and antibiotics. 64% 
 highlighted improved access to 
prescription medicines with PP. 
Perepelkin 
(2011) [49] 
Better understand public perceptions of 
pharmacists, and the acceptance of possible 
expanded roles for pharmacists, including 
prescribing authority 
No standardised 
definition provided 
Canada  General public (n=1283, 
RR 31.4%) 
Questionnaire Emergency situations, renewal of 
long-term medications and changing 
medications’ frequency or strength 
were the most accepted scenarios 
for PP. 
Erhun, 
Osigbesan and 
Awogbemi 
(2013) [50] 
Determine the views of pharmacists and 
physicians on PP, appropriateness and the 
possible contribution to the healthcare 
system if pharmacists prescribe 
No standardised 
definition provided 
Nigeria Pharmacists (n=300, RR 
61%) and physicians 
(n=400, RR 40%) 
Questionnaire 77.5% of pharmacists supported 
while 74.4% of physicians opposed 
PP. However, if there was no doctor, 
some physicians supported PP. 
Reasons for opposition were legal 
provision and professional 
incompetence. 
Hoti, Hughes 
and Sunderland 
(2013) [51] 
Compare the attitudes of hospital and 
community pharmacists regarding an 
expanded prescribing role 
An overview of 
international 
models presented 
Australia Pharmacists (n=2592, 
RR 40.4%) 
Questionnaire Community pharmacists supported 
IP and emergency prescribing. 
Hospital pharmacists supported SP 
for heart failure and anticoagulant 
therapies; and IP for anticoagulant 
therapies. 
Auta et al. 
(2014) [52] 
Explore the views of patients of community 
pharmacists on their consultation 
experiences, and the possible extension of 
prescribing rights to pharmacists in Nigeria 
No standardised 
definition provided 
Nigeria Patients (n=432, RR 
86.6%) 
Questionnaire 92.5% supported PP. 79.7% favored 
restricted formulary prescribing, and 
71.9% prefer to see a doctor if their 
conditions get worse. 
Moore, 
Kennedy and 
McCarthy 
(2014) [53] 
Explore GP–pharmacist relationship, gain 
insight into communication between the 
professions and evaluate opinion on 
extension of the role of the community 
pharmacist 
No standardised 
definition provided 
Ireland Doctors (n=500, RR 
52%) and community 
pharmacists (n=335, RR 
62%) 
Questionnaire Compared to doctors, pharmacists 
were more supportive of PP. 82% of 
GPs and 96% of pharmacists favored 
pharmacists dealing with minor 
ailments. 
Hale et al. 
(2016) [54] 
Assess whether patient satisfaction with the 
pharmacist as a prescriber and patient 
experiences in two settings of collaborative 
doctor-pharmacist prescribing may be 
barriers to implementation of PP 
No standardised 
definition provided 
Australia Patients in pre-
admission (n=200, RR 
91%) and sexual health 
(n=17, RR 85%) clinics 
Questionnaire Almost all patients (98% in pre-
admission and 97% in sexual health 
clinic) were satisfied with the 
consultation. 
Ung et al. 
(2016) [55] 
Explore how pharmacists can prescribe oral 
antibiotics to treat a limited range of 
infections whilst focusing on their confidence 
and appropriateness of prescribing 
Current practice of 
Australian 
pharmacists 
presented 
Australia  Pharmacists (n=240, RR 
34.2%) 
Questionnaire High levels of appropriate antibiotic 
prescribing were shown for 
uncomplicated urinary tract 
 infections (97.2%), cellulitis (98.2%) 
and adolescent acne (100%). 
Auta et al. 
(2017) [56] 
Explore the views of pharmacists in Nigeria 
on the extension of prescribing authority to 
them, determine their willingness to be 
prescribers and identify the potential 
facilitators and barriers to introducing PP in 
Nigeria 
Provided definition 
of UK models 
Nigeria Pharmacists (n=775, RR 
40.6%) 
Questionnaire 97.1% supported PP. Facilitators for 
PP were increasing patients’ access 
to care and better utilisation of 
pharmacists’ skills. Barriers were 
medical resistance and pharmacists’ 
inadequate diagnosis skills. 
Khan et al. 
(2017) [57] 
Assess the attitudes of rural population 
towards PP and their interest in using 
expanded PP services 
No standardised 
definition provided 
India  General public (n=480, 
RR 85.4%) 
Questionnaire 81.5% supported PP. Participants 
with low income and tertiary 
education showed more interest 
towards PP (p<0.05). 
Post-implementation of pharmacist prescribing 
Eng, McCormick 
and Kimberlin 
(1990) [19] 
Examine the attitudes and self-reported 
prescribing activities of a sample of Florida 
pharmacists interviewed 6 months and 12 
months after enactment of the Florida 
Pharmacist Self-Care Consultant Law (SCCL) 
No standardised 
definition provided 
USA  Pharmacists (prescribers 
and non-prescribers) 
(n=200, RR 97% for 
Phase 1; n= 131, RR 
66% for Phase 2) 
Interview 
(Quantitative 
approach) 
Prescribers perceive that the law 
positively affected their relationships 
with patients. Both prescribers and 
non-prescribers believed that the law 
has not affected their relationships 
with physicians. 
White-Means 
and Okunade 
(1992) [20] 
Assess the current status of IP by Florida 
pharmacists two years after the law was 
enacted, examine correlates of the choice to 
prescribe, and discuss policy implications of 
the findings 
Provided a 
description of the 
SCCL 
USA  Pharmacists (prescribers 
and non-prescribers) 
(n=1800, RR 32.3%) 
Questionnaire Prescribers are more likely to 
perceive they have enough training 
to prescribe and to view their skills 
as comparable to those of 
physicians, but less likely to think a 
PharmD is needed. 
Erwin, Britten 
and Jones 
(1996) [21] 
Explore GPs’ views on various drugs being 
dispensed by community pharmacists without 
a prescription to determine whether these 
views have changed since 1990 
No standardised 
definition provided 
UK  Doctors (not exposed to 
PP) (n=250, RR 69% for 
fundholding, n= 600, RR 
57% for non-
fundholding practices) 
Questionnaire GPs overall level of approval for PP 
had increased. GPs from fundholding 
practices agreed to a slightly wider 
range of drugs being made available 
over-the-counter than those from 
non-fundholding practices. 
George et al. 
(2006a) [22] 
Explore SP pharmacists’ early experiences of 
prescribing and their perceptions of the 
prescribing course 
Provided definition 
of UK models 
Great 
Britain 
SP pharmacist (n=518, 
RR 82.2%) 
Questionnaire Better patient management and 
funding issues were the main benefit 
and barrier respectively. Predictors 
of SP included time since SP 
registration; confidence and 
practicing in a setting other than 
community pharmacy. 
 Hobson and 
Sewell (2006a) 
[23] 
Study the implementation of SP by 
pharmacists within primary care trusts (PCTs) 
and secondary care trusts (SCTs) in England 
Provided definition 
of UK models 
UK  Pharmacists (not 
exposed to PP) (n=143, 
RR 68% for SCT; n= 
271, RR 68% for PCT) 
Questionnaire Additional training required around 
the clinical area of practice for SCT 
and the completion of continuing 
professional development for PCT 
respondents. 
Hobson and 
Sewell (2006b) 
[24] 
Provide data on the views of chief 
pharmacists and PCT pharmacists on the 
risks and concerns surrounding SP 
An overview of 
global experiences 
presented 
UK  Chief pharmacists and 
PCT pharmacists (not 
exposed to PP) (n=143, 
RR 68% for SCT; n= 
271, RR 68% for PCT) 
Questionnaire There was positively about 
implementing SP but concerns rose 
over training and professional 
competency/responsibility. 
Smalley (2006) 
[25] 
Evaluate patients’ experience of our 
established pharmacist-led SP hypertension 
clinic 
No standardised 
definition provided 
UK Patients who 
experienced SP (n=127, 
RR 87%) 
Questionnaire 91% continued to attend. 57% 
found the care they received was 
better than previous care. 86% 
understood their condition more, 
were more involved in decision-
making and could easily schedule 
appointment. 
George et al. 
(2007) [26] 
Investigate the challenges experienced by 
pharmacists in delivering SP services, explore 
their perceptions of benefits of SP and obtain 
feedback on both SP training and 
implementation 
Provided definition 
of UK SP model 
Great 
Britain 
SP pharmacists (n=488, 
RR 82.2%) 
Questionnaire Better patient management was the 
main benefit. Barriers include lack of 
organisational recognition of SP and 
funding. Greater emphasis on clinical 
skills development should be part of 
the SP course. 
Stewart et al. 
(2008) [27] 
Explore patients’ perspectives and 
experiences of pharmacist SP in Scotland 
Provided definition 
of UK SP model 
UK  Patients who 
experienced SP (sample 
size not clear, RR 
57.2%) 
Questionnaire 89.3% were satisfied with the 
consultation, 78.7% thought it was 
comprehensive and most would 
recommend PP to others. However, 
65% would prefer to consult a 
doctor. 
Stewart et al. 
(2009b) [28] 
Determine the awareness of, views on, and 
attitudes of members of the Scottish general 
public toward nonmedical prescribing, with an 
emphasis on PP 
Provided definition 
of UK models 
UK General public (exposed 
and non-exposed to PP) 
(n=500, RR 37.1%) 
Questionnaire 56.6% were aware of non-medical 
prescribing. More than half 
supported PP. Concerns rose about 
privacy despite acknowledging its 
enhanced convenience. 
McCann et al. 
(2011) [29] 
Capture information on PP in Northern 
Ireland 
Provided definition 
of UK models 
UK Pharmacists who were 
identified as qualified 
prescribers (n=105, RR 
76%) 
Questionnaire Benefits for patient care and 
pharmacist were reported. IP was 
viewed as the way forward but 
concerns were raised about 
prescribing without a diagnosis or 
beyond the team setting. 
 McIntosh et al. 
(2011) [30] 
Investigate newly registered pharmacists’ 
awareness of PP and views on potential 
future roles as prescribers 
No standardised 
definition provided 
Great 
Britain 
Newly registered 
pharmacists (not 
exposed to PP) 
(n=1658, RR 25.2%) 
Questionnaire 86.4% were interested in 
prescribing. Training is needed in 
clinical examination, patient 
monitoring and medico-legal aspects 
of prescribing. 66.3% thought the 
current requirement for SP was 
appropriate. 
Stewart et al. 
(2011) [31] 
Evaluate the views of patients across primary 
care settings in Great Britain who had 
experienced PP 
No standardised 
definition provided 
Great 
Britain 
Patients who 
experienced PP 
(n=1622, RR 29.7%) 
Questionnaire The vast majority were satisfied with 
their consultation, believed their 
pharmacist prescribed as safely as 
their GP and considered them 
approachable and thorough.  
Hutchison et al. 
(2012) [32] 
Determine reasons for the slow adoption of 
prescribing authority by hospital pharmacists 
in the Canadian province of Alberta 
An overview of PP 
in Canada 
presented 
Canada  Pharmacists (not 
exposed to PP) (n=500, 
RR 62.8%) 
Questionnaire The value of PP motivates 
pharmacists to apply for PP. Barriers 
include the lengthy application 
process, increased liability and 
documentation requirements. 
MacLure et al. 
(2013) [33] 
Explore the views of the Scottish general 
public on non-medical prescribing 
Provided definition 
of UK models 
UK  General community in 
Scotland (exposed and 
non-exposed to PP) 
(n=500, RR 37.1%) 
Questionnaire There was lack of awareness of NMP 
knowledge and training but support 
for a limited range of prescribing. 
Barriers included lack of access to 
medical records and issues with 
privacy and confidentiality. 
Tinelli et al. 
(2013) [34] 
Obtain feedback from primary care patients 
on the impact of prescribing by nurse 
independent prescribers (NIPs) and 
pharmacist independent prescribers (PIPs) on 
experiences of the consultation, the patient–
professional relationship, access to 
medicines, quality of care, choice, 
knowledge, patient-reported adherence and 
control of their condition 
Provided definition 
of UK models 
UK  Patients who 
experienced PP (n=975, 
RR 30%) 
Questionnaire Satisfaction and confidence with PIP 
were high. When comparing NMP to 
doctor prescribing, most reported no 
difference in their experience of 
care. 
Hill et al. 
(2014) [35] 
Not explicitly stated: 
Explore the acceptability of PP in addiction 
services in NHS Lanarkshire amongst the 
stakeholders and service users 
Provided definition 
of UK models 
UK  Patients (n=110, RR 
78.2%), PP (n=5, 
100%), medical 
prescribers (n=12, RR 
50%) 
Questionnaire PP is seen as effective and preferred 
by patients. Although doctors have 
more reservations, the majority 
believed it was beneficial. All thought 
IP would be more beneficial. 
 Mansell et al. 
(2015) [36] 
Determine whether patients prescribed 
treatment for minor ailments by a pharmacist 
symptomatically improve within a set time 
frame 
No standardised 
definition provided 
Canada Patients who 
experienced PP (all 
population was included) 
Questionnaire Condition significantly/completely 
improved in 80.8% with only 4% 
experiencing bothersome side 
effects. Trust in pharmacists and 
convenience were the common 
reasons for choosing a pharmacist 
over a physician.  
Bourne et al. 
(2016) [37] 
Determine the current and proposed future IP 
practice of UK clinical pharmacists working in 
adult critical care 
No standardised IP 
definition provided 
UK UK Clinical Pharmacy 
Association members 
(prescribers and non-
prescribers) (n=404, RR 
33%) 
Questionnaire Over a third were IP, and 70% 
intended to be prescribers within the 
next 3 years. Experience and 
working in a team facilitated IP. 
Pharmacists reported significant 
positives in patient care and job 
satisfaction. 
Isenor et al. 
(2017) [58] 
To identify the relationship between barriers 
and facilitators to pharmacist prescribing and 
self-reported prescribing activity using the 
Theoretical Domains Framework version 2 
(TDF(v2)) 
An overview of PP 
in Nova Scotia 
(Canada) 
presented 
Canada Pharmacists (prescribers 
and non-prescribers) 
(n= 1100, RR 8%) 
Questionnaire The three domains most positive 
attitudes associated with prescribing 
were Knowledge (84 %), 
Reinforcement (81%) and Intentions 
(78 %). The largest effect on 
prescribing activity was the Skills 
domain. 
Abbreviations: 
NMP: Non-medical Prescribing 
IP: Independent Prescribing 
SP: Supplementary Prescribing 
PP: Pharmacist Prescribing 
 
   
 Table 4: Characteristics and key findings of included qualitative studies (n=21) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition and 
model of PP 
discussed 
Country 
of focus 
Stakeholder 
population studied 
(number of 
participants)  
Study design 
and methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Weeks, 
Marriott and 
George (2010) 
[74] 
Pilot a UK NMP course for Australian hospital 
pharmacists and elicit participants’ views on 
NMP and experiences of the training 
Provided 
definition of UK 
models 
Australia Hospital pharmacists 
(n=15) 
Focus group Confidence, competency, legislative 
constraints, acceptance by other 
health providers, assessment 
requirements and university 
documentation were highlighted. 
Hatah et al. 
(2013) [75] 
Evaluate GPs’ perceptions of pharmacists’ 
contributions to services traditionally 
undertaken by GPs 
Provided 
definition of IP 
New 
Zealand 
Doctors (n=18) Interview GPs were more accepting of 
pharmacists’ medication reviews 
than of PP unless appropriate 
controls, close collaboration and co-
location of services took place. 
Pojskic et al. 
(2014) [76] 
Ascertain the initial perceptions of the Ontario 
government and health professional 
stakeholder groups regarding the prospect of 
prescriptive authority for pharmacists 
An overview of 
the models 
present 
internationally 
and in Ontario 
presented 
Canada  Key informants from 
the Ontario 
government and 
provincial pharmacy 
and medical regulatory 
colleges and 
professional 
associations (n=17) 
Qualitative study 
using policy 
documents and 
semi-structured 
interviews 
Pharmacy organisations and Ontario 
government representatives 
supported while medical 
organisations opposed PP. 
Bajorek et al. 
(2015) [77] 
Explore the perspectives of GP super clinic 
staff on current and potential (future) 
pharmacist-led services provided in this 
setting 
No standardised 
definition 
provided 
Australia  Doctors (n=3), 
pharmacist (n=1), 
nurse (n=1), business 
manager (n=1) and 
reception staff (n=3) 
Interview Positive working relationships, 
satisfaction with pharmacist’s 
current role and support for 
potential future roles were reported. 
Although GPs had differing views 
about PP, they saw several benefits 
for it. 
Auta, 
Strickland-
Hodge and 
Maz (2016) 
[78] 
Investigate stakeholders’ views on granting 
prescribing authority to pharmacists in Nigeria 
No standardised 
definition 
provided 
Nigeria Policymakers, 
pharmacists, doctors 
and patient group 
representative (n=43) 
Interview Non-medical stakeholders supported 
PP while doctors were reluctant to 
do so. Benefits (access to 
medicines) and barriers 
(pharmacists’ diagnosis skills) were 
stated. 
Le, Braunack-
Mayer and 
Laurence 
(2017) [79] 
Explore the potential impact of a collaborative 
prescribing model for Opioid Substitution 
treatment (OST) on patients, pharmacists and 
health provider relationships from the 
perspective of pharmacists and patients 
No standardised 
definition 
provided 
Australia  OST patients (n=14) 
and community 
pharmacists (n=18) 
Interviews with 
patients and 
focus groups 
with pharmacists 
Benefits included improved 
continuity of care and convenience. 
Changes to healthcare relationships 
and ensuring adequate support of PP 
were highlighted. 
 Post-implementation of pharmacist prescribing 
Lloyd and 
Hughes 
(2007) [59] 
Explore the views and professional context of 
pharmacists and physicians (who acted as 
their training mentors), prior to the start of 
SP training 
Provided 
definition of UK 
SP model 
UK  Pharmacists 
prescribers (n=47) and 
their mentors (n=35) 
Focus groups 
with pharmacists 
and face-to-face 
semi-structured 
interviews with 
the mentors 
SP was anticipated to improve 
patient care and interprofessional 
relationships. Loss of diversity, 
deskilling of junior doctors, safety 
and professional encroachment were 
reported. 
Tully et al. 
(2007) [60] 
Investigate the views and experiences of 
pharmacists in England before and after they 
registered as SP 
Provided 
definition of UK 
SP model 
UK  Pharmacists (before 
and after registering as 
SPs) (n=8) 
Interview Pharmacists thought training would 
legitimise their current informal 
prescribing. Pharmacists already 
involved with prescribing were more 
likely to work as prescribers. 
Blenkinsopp et 
al. (2008) 
[61] 
Explore GPs perceptions of the advantages 
and disadvantages of pharmacist SP and the 
future introduction of IP 
Provided 
definition of UK 
models 
UK  Doctors who had 
experienced SP (n=13) 
Focus group Not all referred patients to the PP. 
Those GPs who referred patients 
described benefits with some 
ambivalence. 
Stewart et al. 
(2009a) [62] 
Explore the perspectives of pharmacist SP, 
their linked independent prescribers and 
patients, across a range of settings, in 
Scotland, towards PP 
Provided 
definition of UK 
models 
UK  SP pharmacists (n=9), 
their mentors (n=8) 
and patients (n=18) 
Interview All were supportive of SP identifying 
benefits for patients and the wider 
healthcare. Pharmacists were keen 
on IP but not doctors citing 
inadequate examination skills. 
Weiss and 
Sutton (2009) 
[63] 
Investigate the potential threat to medical 
dominance posed by the addition of 
pharmacists as prescribers in the UK and 
explore the role of prescribing as an indicator 
of professional power, the legitimacy and 
status of new PP and the forces influencing 
professional jurisdictional claims over the task 
of prescribing 
Provided 
definition of UK 
models 
UK SP pharmacists (n=23) Interview Facilitators include blurred 
definitions of prescribing, 
competence and a team approach to 
patient management. 
Hobson, Scott 
and Sutton 
(2010) [64] 
Explore the opinions of patients on the 
development of NMP 
Provided 
definition of UK 
models 
UK  Patients (exposed and 
not exposed to PP) 
(n=18) 
Interview Concerns rose about clinical 
governance, privacy and space. 
Participants acknowledged 
pharmacists’ knowledge and 
accessibility. 
Lloyd, 
Parsons, and 
Hughes 
(2010) [65] 
Explore the context and experiences, in 
relation to the practice of SP, of pharmacists 
and physicians (who acted as their training 
mentors) at least 12 months after 
pharmacists had qualified as SP 
Provided 
definition for 
UK IP model 
UK  SP pharmacists (n=40) 
and their mentors 
(n=31) 
Focus groups 
with pharmacists 
and face-to-face 
semi-structured 
interviews with 
the mentors 
PP was perceived to reduce doctors’ 
workload and improved continuity of 
care. IP was seen as contentious by 
mentors due to the diagnostic 
element. 
 Tonna et al. 
(2010) [66] 
Explore pharmacists’ perceptions of the 
feasibility and value of PP of antimicrobials in 
secondary care in Scotland 
Provided 
definition of UK 
models 
UK  Senior hospital 
pharmacists 
(prescribers and non-
prescribers) (n=37) 
Focus group Perceived benefits included quicker 
access to medicines, reduced risk of 
resistance and better application of 
evidence-based medicine. 
Dawoud et al. 
(2011) [67] 
Investigate pharmacist prescribers’ views and 
experiences of the early stages of SP 
implementation 
Provided 
definition for 
independent, 
dependent and 
collaborative 
prescribing 
models 
UK SP pharmacists (n=16) Interview Benefits reported on patient care 
and pharmacists’ job satisfaction. SP 
limited pharmacists’ freedom in 
decision making. Hence, IP was 
supported. 
McCann et al. 
(2012a) [68] 
Explore patients’ perspectives of pharmacists 
as prescribers 
Provided 
definition of UK 
models 
UK  Patients who 
experienced PP (n=34) 
Focus group Patients supported PP especially in a 
team setting. However, there was a 
lack of awareness of PP role. 
McCann et al. 
(2012b) [69] 
Provide an in-depth understanding of PP from 
the perspective of pharmacists, medical 
colleagues and other key stakeholders in 
Northern Ireland  
Provided 
definition of UK 
SP model 
UK  PP (n=11), medical 
colleagues (n=11) and 
other key stakeholders 
(n=13) 
Interview PP resulted in a more holistic 
approach to care. Challenges include 
working within areas of competency, 
complex conditions and resistance 
by older doctors. 
Makowsky et 
al. (2013) 
[70] 
Understand what factors influence 
pharmacists’ adoption of prescribing using a 
model for the Diffusion of Innovations in 
healthcare services 
An overview of 
prescribing 
authority in 
Alberta 
presented 
Canada  Pharmacists 
(prescribers and non-
prescribers) (n=38) 
Interview PP was dependent on the innovation 
itself, adopter, system readiness, 
practice setting, communication and 
influence. 
Deslandes, 
John and 
Deslandes 
(2015) [71] 
Explore the views and experiences of patients 
with mental illness on being managed by a 
pharmacist SP in a secondary care outpatient 
setting 
Provided 
definition of UK 
SP model 
UK Patients with mental 
illness who 
experienced SP (n=11) 
Exploratory 
study using 
semi-structured 
interviews and 
self-completion 
diaries 
Patients supported PP and felt they 
were involved in decisions 
concerning their healthcare. 
Feehan et al. 
(2016) [72] 
Investigate the perceived demand for and 
barriers to PP in the community pharmacy 
setting 
An overview of 
prescribing 
authority in 
USA presented 
USA Consumers (n=19), 
community 
pharmacists (n=20) 
and re-imbursement 
decision-makers (n=8) 
(not exposed to PP) 
Interview Consumers opposed. Pharmacists 
supported PP for limited conditions. 
Reimbursement decision-makers 
were most receptive. Barriers 
included awareness of PP, 
pharmacist training, conflicts of 
interest and liability issues. 
McIntosh and 
Stewart 
(2016) [73] 
Explore the views and reflections on PP of UK 
pre-registration pharmacy graduates 
No standardised 
definition 
provided 
UK  Pre-registration 
pharmacy graduates 
(n=12) 
Interview Support was related to professional 
development. Barriers included lack 
of organisational strategy, 
confidence and workload. 
 Abbreviations: 
NMP: Non-medical Prescribing 
IP: Independent Prescribing 
SP: Supplementary Prescribing 
PP: Pharmacist Prescribing 
 
   
 Table 5: Characteristics and key findings of included mixed-methods studies (n=3) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition and 
model of 
pharmacist 
prescribing 
discussed 
Country 
of focus 
Stakeholder 
population studied 
(sample size) 
Study design and 
methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Hanes, and 
Bajorek 
(2005) [81] 
Explore the views of a sample of Australian 
hospital pharmacists on prescribing 
privileges 
Provided a 
definition for 
dependent 
prescribing 
Australia Hospital pharmacists 
(n=10) and teacher 
practitioners (n=5) (15 
completed the 
questionnaire, 8 
participated in the 
focus groups) 
Questionnaire and 
focus group 
Benefits include more 
efficient/improved 
pharmaceutical care 
and reduced healthcare 
costs. Physician 
opposition was a 
barrier. Training and 
accreditation beyond 
registration was 
deemed necessary. 
Vracar and 
Bajorek 
(2008) [82] 
Explore Australian GPs’ views on extending 
prescribing rights to pharmacists, the 
appropriateness of PP models, and the 
influence of GPs’ characteristics on their 
preference for a particular PP model 
An overview of 
international 
models presented 
Australia Doctors (150 
approached, 22 filled 
the questionnaire and 
10 participated in the 
interview) 
Questionnaire and 
semi-structured 
interview 
Repeat prescribing and 
prescribing by referral 
were the most 
favoured. Safety 
issues, lack of 
awareness of 
pharmacist training 
and capabilities, clinical 
responsibility, GP–
patient relationship and 
remuneration were 
raised. 
Post-implementation of pharmacist prescribing 
Baqir (2010) 
[80] 
Evaluate the extent of PP and identify some 
of the barriers to maintaining and 
developing such services 
No standardised 
definition 
provided 
UK  Pharmacists who 
undertook a 
prescribing course (179 
were invited to 
participate, 98 filled 
the questionnaire but 
not clear how many 
Multiple methods: 
Questionnaire, focus 
groups, documents 
review and interviews 
In secondary care, 
easy access to medical 
records and 
prescription pads as 
well as close working 
relationships with 
doctors were 
facilitators. The major 
 were involved in the 
focus groups) 
barrier was lack of a 
clear strategy at 
organisational level. 
Abbreviations: 
PP: Pharmacist Prescribing 
 
 
 Table 6: Facilitators and barriers to pharmacist prescribing 
Facilitators  Pharmacists’ personal qualities (communication skills, training, experience, and 
enthusiasm) 
 Practice setting (secondary vs primary vs community) 
 Organisational, managerial, and medical colleagues’ support 
 Resources (workforce, space, access to medical records) 
Barriers  Pharmacists’ skills (clinical examination and diagnostic skills) 
 Resources (workforce, access to medical records, space, time) 
 Physicians and organisational support 
 Funding 
 Legal aspects (accountability, conflict of interest) 
 Pharmacy practice recognition 
 
